Franco Stevanato

Person

Last mentioned: Mar 5, 2026

Stories mentioning Franco Stevanato 2

pharma Bullish

GLP-1 Surge Powers Stevanato Growth as Pulmonx Navigates Sales Restructuring

Stevanato Group reported a 50% surge in GLP-1 related revenue for 2025, underscoring the massive impact of the weight-loss drug market on pharmaceutical supply chains. Conversely, medical device maker Pulmonx is undergoing a significant transition following a 50% turnover in its sales organization and a dip in U.S. quarterly revenue.

14 sources
market-trends Bullish

GLP-1 Surge Drives Stevanato Growth as MedTech Sector Pivots to Efficiency

Stevanato Group reported robust 2025 results fueled by a 50% surge in GLP-1 related revenue, while medical device maker Pulmonx initiated aggressive cost-cutting measures following a U.S. revenue decline. The divergence highlights a shifting healthcare landscape where specialized biopharma supply chains are outperforming traditional niche medical devices.

14 sources